Logo

Zyomyx Signs on GlaxoSmithKline for Protein Biochips

Aug 16, 2002

NEW YORK, Aug. 16-GlaxoSmithKline has agreed to be an early access customer of Zyomyx's line of protein biochips, Zyomyx said today.

 

Zyomyx has developed biochips and a profiling system that permits researchers to track expression of 30 human cytokines in serum samples. According to the company, the system can be used in drug discovery, target validation, biomarker studies and drug candidate evaluation.

 

The companies did not reveal financial details of the agreement.

 

The clinical testing company Specialty Laboratories also has an early access agreement with Zyomyx.

 

Breaking News
The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.